Interleukin-6 mediates resistance to PI3K-pathway –targeted therapy in lymphoma

The phosphoinositol 3-kinase (PI3K) pathway is associated with poor prognosis of hematologic malignancies, providing a strong rationale for the use of PI3K inhibitors in the treatment of malignant lymphoma. Ho...

Source: BMC Cancer - October 10, 2019 Category: Cancer & Oncology Authors: Joo Hyun Kim, Won Seog Kim and Chaehwa Park Tags: Research article Source Type: research